Fox Chase finds that lung cancer patients respond to erlotinib following cetuximab therapy
Sunday, August 2, 2009 - 15:42
in Health & Medicine
SAN FRANCISCO (August 1, 2009) -- Non-small cell lung cancer patients who have progressed on a cetuximab-containing regimen may respond to erlotinib, Fox Chase Cancer Center researchers reported today at the annual meeting of the International Association for the Study of Lung Cancer.